Dravet Syndrome (DS) Epidemiology Forecast 2025-2034

Various studies suggest that the incidence of Dravet syndrome (DS) ranges between 1:16,000 and 1:46,000. It is estimated that Dravet syndrome patients carry a 15-20% mortality rate, often due to sudden unexpected death in epilepsy (SUDEP), long seizures, infections, and accidents like drowning, according to the Dravet Syndrome Foundation.

Dravet Syndrome (DS) Epidemiology Forecast Report Coverage

The “Dravet Syndrome (DS) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Dravet syndrome (DS). It projects the future incidence and prevalence rates of Dravet syndrome (DS) across various populations. The study covers age and type as major determinants of the Dravet syndrome (DS)-affected population. The report highlights patterns in the prevalence of Dravet syndrome (DS) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Dravet syndrome (DS) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Dravet Syndrome (DS): Disease Overview

Dravet syndrome (DS) is a rare and severe form of epilepsy. It begins in infancy, typically before 1 year of age, and is caused by mutations in the SCN1A gene. Frequent, prolonged seizures are the key features of this disease, which can be triggered by fever or other factors. Children with Dravet syndrome often experience developmental delays, especially in language and motor skills. Some patients also show signs of autism, hyperactivity, or other behavioral concerns. The condition has a high mortality rate and early intervention is needed to improve the quality of life of the affected individual.

Dravet Syndrome (DS): Treatment Overview

In Dravet syndrome, a combination of therapies is used to manage seizures, as they are often resistant to traditional epilepsy medications. These may include anticonvulsants, the ketogenic diet, cannabidiol (CBD), and vagus nerve stimulation (VNS) in certain cases. Valproate (Depakote) and Levetiracetam (Keppra) are the commonly prescribed anticonvulsant medications. Topiramate (Topamax) and Clobazam are also recommended for some patients to control seizures. The ketogenic diet and modified Atkins diet may also help with seizure control.

Epidemiology

The Dravet syndrome (DS) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Dravet syndrome (DS) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Dravet syndrome (DS) and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• In the United States, Canada, Japan, Germany, France, and the United Kingdom, about 35,000 people are affected by Dravet syndrome, with no specific geographic or ethnic concentration.
• According to the Orphanet, Dravet syndrome has an average prevalence of 1 in 30,000 at birth, with a range between 1 in 15,000 and 40,000.
• Dravet syndrome occurs in about 1 in 15,700 people, with most patients having a mutation in the SCN1A gene, as per the Dravet Syndrome Foundation.
• About 85% of Dravet syndrome cases are caused by SCN1A mutations, with 5-10% linked to GEFS+ or genetic epilepsy with febrile seizures plus. Around 5% of female cases are due to PCDH19 mutations.

Country-wise Dravet Syndrome (DS) Epidemiology

The Dravet syndrome (DS) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Dravet syndrome (DS) varies significantly between countries due to differences in genetic factors, healthcare access, diagnostic practices, and awareness of the condition. Additionally, differences in healthcare infrastructure and access to specialized care can lead to variations in reported prevalence and outcomes. In the United States, around 1 in 16,000 babies are born with Dravet syndrome.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Dravet syndrome (DS) based on several factors.
• The Dravet Syndrome (DS) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of Dravet syndrome (DS) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Dravet syndrome (DS) epidemiology in the 8 major markets?
• What will be the total number of patients with Dravet syndrome (DS) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Dravet syndrome (DS) in the 8 major markets in the historical period?
• Which country will have the highest number of Dravet syndrome (DS) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Dravet syndrome (DS) during the forecast period of 2025-2034?
• What are the currently available treatments for Dravet syndrome (DS)?
• What are the disease risks, signs, symptoms, and unmet needs of Dravet syndrome (DS)?

This product will be delivered within 3-5 business days.